You are here

Prices & Quotes - UK Markets - Polarean Imaging (POLX)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 56.00p
Change Today:
-1.00p
Market Cap:
117.18m
Sector:
Health Care Equipment & Services

Polarean Imaging progresses to Phase III trial of hyperpolarised 129-Xenon

By Josh White

Date: Thursday 23 Aug 2018

LONDON (ShareCast) - (Sharecast News) - Medical imaging technology company Polarean Imaging announced on Thursday that the first patient has been enrolled in its Phase III FDA clinical trial, which aims to demonstrate non-inferiority of its drug-device combination using hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved comparator.
The AIM-traded firm said it was now in the process of the Phase III clinical trial.

It said the trial was a 'head-to-head' non-inferiority trial testing 129Xe MRI against 133-Xenon (133Xe) scintigraphy, and it would be evaluating two patient populations - candidate patients for lung lobe resection, and lung transplant procedures - for 80 patients in total.

The Phase III trial was taking place at two US sites - Duke University and the University of Virginia.

Polarean said the Phase III trial followed on from the completion of a pilot study in which 10 patients with COPD were assessed using both Polarean's technology and 133Xe scintigraphy.

In that study the design and analysis methods of the Phase III trial were successfully demonstrated.

"The entire company is thrilled to have initiated our Phase III trial, after all the hard work of preparation," said Polarean chief executive Richard Hullihen.

"We would like to thank our shareholders for their support, without which this would not have been possible.

"We also thank our clinical and research collaborators as their skill and expertise has been invaluable in enabling us to reach this important milestone."

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

POLX Market Data

Currency UK Pounds
Price 56.00p
Change Today -1.00p
52 Week High 106.50p
52 Week Low 42.80p
Volume 553,585
Shares Issued 209.25m
Market Cap 117.18m
Beta 0.02

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. half sector star
  3. empty sector
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. half sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector

POLX Dividends

No dividends found

Trades for 21-Jan-2022

Time Volume / Share Price
17:05 98,500 @ 56.00p
15:35 50,000 @ 56.20p
16:35 1,700 @ 56.00p
16:24 16,201 @ 54.55p
16:14 10,000 @ 54.55p

POLX Key Personnel

CEO Richard Hullihen
CFO Charles Osborne